Melatonin mitigates vincristine-induced peripheral neuropathy by inhibiting TNF-α/astrocytes/microglial cells activation in the spinal cord of rats, while preserving vincristine's chemotherapeutic efficacy in lymphoma cells

Toxicol Appl Pharmacol. 2024 Nov:492:117134. doi: 10.1016/j.taap.2024.117134. Epub 2024 Oct 24.

Abstract

Vincristine (VCR), an anti-tubulin chemotherapy agent, is known to cause peripheral and central nerve damage, inducing severe chemotherapy-induced peripheral neuropathy (CIPN). Although melatonin has been recently recognized for its potential anti-neuropathic effects, its efficacy in countering VCR-induced neuropathy remains unclear. This study examines the neuroprotective potential of melatonin against VCR-induced neuropathy using a rat model. Neuropathic pain was induced through 10 VCR injections (0.1 mg/kg/day i.p.), administered in two five-day cycles with a two-day break. Melatonin treatment started two days before VCR administration and continued daily throughout the experiment. Rats were assigned to five groups: control, VCR, and three melatonin-treated groups receiving VCR with melatonin (5, 10, or 20 mg/kg/day i.p.). We assessed mechanical (von-Frey and Randall-Selitto tests) and thermal (hot-plate and tail-flick tests) hyperalgesia, motor coordination (rotarod test), and sciatic nerve conduction velocity (NCV). Changes in body weight, spinal cord histopathology (H&E), and proinflammatory markers (TNF-α, IL-1β, and IL-6), reactive astrocytes (GFAP) and microglial cells (IBA-1) were also assessed, as well as spinal cord degeneration (Nissl stain) and demyelination (LFB stain and MBP). Finally, the effect of melatonin on the cytotoxic activity of VCR against EL4 lymphoma cells was assessed using an MTT assay. Our results indicated that melatonin coadministration with VCR preserved spinal cord architecture, elevated nociceptive thresholds, improved motor coordination, enhanced NCV, and maintained normal body weight gain. Melatonin also reduced inflammation, decreased reactive astrocytes and microglia, and prevented neurodegeneration and demyelination in the spinal cord. Importantly, melatonin did not affect VCR's cytotoxic activity in cancer cells.

Keywords: Behavioral tests; Central pain sensitization; Chemotherapy neurotoxicity; Melatonin; Neuroprotection; Vincristine.

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Antineoplastic Agents, Phytogenic / toxicity
  • Astrocytes* / drug effects
  • Astrocytes* / pathology
  • Cell Line, Tumor
  • Hyperalgesia / chemically induced
  • Hyperalgesia / drug therapy
  • Hyperalgesia / prevention & control
  • Lymphoma / drug therapy
  • Lymphoma / pathology
  • Male
  • Melatonin* / pharmacology
  • Melatonin* / therapeutic use
  • Microglia* / drug effects
  • Neuralgia / chemically induced
  • Neuralgia / drug therapy
  • Neuralgia / prevention & control
  • Neuroprotective Agents / pharmacology
  • Peripheral Nervous System Diseases / chemically induced
  • Peripheral Nervous System Diseases / drug therapy
  • Peripheral Nervous System Diseases / pathology
  • Peripheral Nervous System Diseases / prevention & control
  • Rats
  • Rats, Sprague-Dawley
  • Spinal Cord* / drug effects
  • Spinal Cord* / metabolism
  • Spinal Cord* / pathology
  • Tumor Necrosis Factor-alpha* / metabolism
  • Vincristine* / toxicity

Substances

  • Melatonin
  • Vincristine
  • Tumor Necrosis Factor-alpha
  • Neuroprotective Agents
  • Antineoplastic Agents, Phytogenic